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Actinic keratoses (AKs) are erythematous, asymptomatic keratotic lesions that usually develop in the second phase of life, and occur predominately in chronic ultraviolet‐exposed skin of light‐skinned individuals.[1](#bjd17632-bib-0001){ref-type="ref"}, [2](#bjd17632-bib-0002){ref-type="ref"} The prevalence of AKs is high: in population‐based data from the Rotterdam Study (RS) and the Australian Skin Cancer Cohort it has been estimated that 24% (the Netherlands) to 60% (Australia) of people older than 50 years have at least one AK.[3](#bjd17632-bib-0003){ref-type="ref"}, [4](#bjd17632-bib-0004){ref-type="ref"} The likelihood of an individual lesion to progress to squamous cell carcinoma (SCC) is \< 1% per year.[5](#bjd17632-bib-0005){ref-type="ref"} However, patients often have multiple AKs indicating cutaneous field dysplasia, which substantially increases their risk of developing skin cancer, mostly SCC and basal cell carcinoma (BCC). Although these tumours account for only a few cancer‐related deaths,[3](#bjd17632-bib-0003){ref-type="ref"}, [6](#bjd17632-bib-0006){ref-type="ref"} premalignant and malignant skin cancers consume substantial health resources and have an impact on the quality of life.[7](#bjd17632-bib-0007){ref-type="ref"}

Despite the high impact of AK‐related care, there is a lack of empirical evidence on the management of AK. The reasons for this are that patients do not necessarily seek care for asymptomatic AK, AK is often a clinical diagnosis and thus not captured in the pathology and cancer registries, and patients can be managed in both primary and secondary care. A single data source is therefore not sufficient to capture the complete healthcare utilization pathway of this group. A previous study by Kirby *et al*. showed a variation in costs for the management of AK within and between regions, which could not be fully explained by patient characteristics, and advocated to identify the care pathways of patients with AK.[8](#bjd17632-bib-0008){ref-type="ref"} The objective of this study was to provide insight in to the management of AKs by describing the healthcare utilization of people with AK in a population‐based cohort and in the primary care and secondary care settings.

Patients and methods {#bjd17632-sec-0007}
====================

Study design {#bjd17632-sec-0008}
------------

To study AK management, a retrospective, multiple database, descriptive cohort study of population‐based data and routine data of people with AK was conducted (Fig. [1](#bjd17632-fig-0001){ref-type="fig"}).

![This research was conducted using three complementary databases and shows a visual record of the position in health care of the data collection of each data source for this research. AK, actinic keratosis; DIS,DRG Information System; GP, general practitioner; IPCI, Integrated Primary Care Information.](BJD-181-544-g001){#bjd17632-fig-0001}

Data sources and study population {#bjd17632-sec-0009}
---------------------------------

### Population‐based cohort: Rotterdam Study {#bjd17632-sec-0010}

The RS is an ongoing population‐based cohort study of nearly 15 000 participants aged 45 years and older from a suburb in Rotterdam in the Netherlands.[9](#bjd17632-bib-0009){ref-type="ref"} Between August 2010 and November 2015, 5517 participants received a full‐body skin examination (FBSE) by dermatologically trained physicians. Standardized forms were used to document the most common skin diseases, including AK and categorizing the total body count into 0, 1--3, 4--9 and ≥ 10 lesions. General practitioner (GP) records before the RS screening visit of participants with AK were manually screened for the presence of previous AK diagnoses (clinical diagnosis by GP or dermatologist, or histologically confirmed), treatments and AK‐related follow‐up visits. As participants with extensive AK were advised to consult their GP, which may have changed their healthcare consumption, only records before the screening visit were evaluated (Fig. [2](#bjd17632-fig-0002){ref-type="fig"}). To assess the total health impact, RS was used to evaluate the management during all AK‐related visits, instead of differentiating between initial and follow‐up visit. Subsequent keratinocyte cancer (KC) development was obtained by linkage of all RS participants with the Dutch Pathology Registry (PALGA), the nationwide registry of histo‐ and cytopathology in the Netherlands (Data [S1](#bjd17632-sup-0001){ref-type="supplementary-material"}; see Supporting Information).[10](#bjd17632-bib-0010){ref-type="ref"}, [11](#bjd17632-bib-0011){ref-type="ref"}

![Each data source had a slightly different period of data collection. The figure shows the data‐collection timeline of each data source. DIS,DRG Information System; FBSE, full‐body skin examination; GP, general practitioner; IPCI, Integrated Primary Care Information; PALGA, the Dutch Pathology Registry.](BJD-181-544-g002){#bjd17632-fig-0002}

### Routine general practitioner records: Integrated Primary Care Information database {#bjd17632-sec-0011}

Integrated Primary Care Information (IPCI) is a central research database with a collection of 2·3 million electronic routine patients records from 265 GP practices in the Netherlands since 1989.[12](#bjd17632-bib-0012){ref-type="ref"} To capture both long‐term follow‐up and recent common practice, a random sample of 1000 patients diagnosed with AK was selected based on a free text algorithm equally divided over 2009/2010 and 2012/2013 (Data [S1](#bjd17632-sup-0001){ref-type="supplementary-material"}; see Supporting Information). Patients were eligible if the GP mentioned AK in the differential diagnosis, AK was confirmed in a histopathological report or AK diagnosis was confirmed by a medical specialist. For eligible patients, the treatment at first GP encounter was extracted, and for those with non‐AK‐specific treatments, such as antibiotics, treatment during the second consultation was included. For the cohort 2009/2010, the frequency of documented BCC and SCC during the remaining follow‐up period was assessed.

### Nationwide hospital claims: DRG Information System database {#bjd17632-sec-0012}

Outpatient care for patients with AK was further evaluated using the national healthcare insurance data from the DRG Information System (DIS). To obtain a perspective on the scope of the problem, data were extracted from opendisdata.nl, which is an openly accessible source on healthcare insurance data.[13](#bjd17632-bib-0013){ref-type="ref"} Health insurance is compulsory for all Dutch residents, and all activities related to diagnosing or treating patients are recorded into a DRG package, which results in a healthcare claim.[14](#bjd17632-bib-0014){ref-type="ref"} The nationwide DIS database receives and manages information on healthcare claims but does not contain personal data. Patients with a dermatologist‐based healthcare claim for a cutaneous premalignancy (code 017) between 2011 and 2015 without previous cutaneous malignancies (code 014) were included. Data were obtained on registered treatments, follow‐up visits and potential subsequent claims for cutaneous malignancies. As a claim for a 'cutaneous premalignancy' can also include other cutaneous premalignancies, an algorithm was developed to identify patients with AK based on healthcare procedures. This algorithm was validated with local (i.e. Erasmus University Medical Center, Rotterdam) patient records resulting in a positive predictive value of 93% (Data [S1](#bjd17632-sup-0001){ref-type="supplementary-material"}; see Supporting Information).

Statistical analysis {#bjd17632-sec-0013}
--------------------

The primary objective was to describe current clinical practice and healthcare utilization. No hypothesis testing and sample‐size calculations were therefore performed. All available data from the RS and DIS were used. For the IPCI data, we considered that 1000 patients with AK was sufficient to describe current clinical practice and was feasible with regard to the time‐consuming manual review of medical records.

Complementing the descriptive analyses, we calculated the relative risk and the 95% confidence interval (CI) for subsequent KC risk among RS participants. The χ^2^‐test was used to evaluate the significance level (*P* = 0·05) between proportions for several values among different AK severity categories.

The analyses were performed using SPSS 21·0 statistical software (IBM Corp., Armonk, NY, U.S.A.) and SAS 9·3 statistical software (SAS Institute Inc., Cary, NC, U.S.A.). The STROBE and RECORD statements were used for reporting the descriptive analyses.[15](#bjd17632-bib-0015){ref-type="ref"}, [16](#bjd17632-bib-0016){ref-type="ref"}

Results {#bjd17632-sec-0014}
=======

Population‐based cohort: Rotterdam Study {#bjd17632-sec-0015}
----------------------------------------

Of the 5517 individuals from the RS who underwent an FBSE, 1510 (27%) were diagnosed with AK. The primary care record was available in 1322 of 1510 participants (87·6%); 55% were male and the mean ± SD age was 61 ± 5 years (Table [1](#bjd17632-tbl-0001){ref-type="table"}).

###### 

Characteristics of the skin screened sample from the population‐based cohort (RS) and a random sample of patients with AK from the GPs database (IPCI)

                                                         Routine GP records (IPCI)                                  RS                    
  ------------------------------------------------------ ---------------------------------------------------------- --------------------- --------------------------------------------------------------------------
  *N*                                                    1000                                                       1322                  
  Male, *n* (%)                                          471 (47)                                                   723 (55)              
  Age, mean ± SD                                         69 ± 12                                                    61 ± 5                
  Number of AK, *n* (%)                                  Described by GP[a,b](#bjd17632-note-0003){ref-type="fn"}   Counted during FBSE   Described by GP during 455 visits[a](#bjd17632-note-0003){ref-type="fn"}
  1--3                                                   528 (53)                                                   724 (55)              117 (26)
  4--9                                                   27 (3)                                                     328 (25)              5 (1)
  \> 10                                                  2 (0·2)                                                    270 (20)              0 (0)
  Present, without absolute numbers                      412 (41)                                                   0 (0)                 333 (73)
  History of cutaneous keratinocyte carcinoma, *n* (%)                                                              325 (25)              
  Basal cell carcinoma                                   53 (5)                                                     271 (20)              
  Squamous cell carcinoma                                23 (2)                                                     69 (5)                

Basic characteristics of patients included in hospital claims data are not available as patient characteristics are not recorded in claims data on a nationwide level. AK, actinic keratosis; FBSE, full‐body skin examination; GP, general practitioner; IPCI, Integrated Primary Care Information; RS, Rotterdam Study. ^a^Based on routine GP care, where FBSE is usually not conducted and the number of AK is usually not explicitly stated in GP records. ^b^Total number does not add up to 1000 as 31 patients ultimately did not have AK.

John Wiley & Sons, Ltd

### Diagnosis {#bjd17632-sec-0016}

Of the 1322 participants with AK and a primary care record, 55% had one to three AKs, 25% had four to nine AKs and 20% had ≥ 10 AKs (Table [1](#bjd17632-tbl-0001){ref-type="table"}). The retrospective GP record review of this population‐based AK cohort, showed that 918 (69%) participants had never visited a healthcare provider for their AK before the FBSE (Table [2](#bjd17632-tbl-0002){ref-type="table"}). Although this decreased slightly with the number of AKs, 50% of those with ≥ 10 AKs had never consulted a physician for AK. No substantial differences in likelihood of having consulted a physician for AKs were observed across age categories and gender (Data [S1](#bjd17632-sup-0001){ref-type="supplementary-material"} tables; see Supporting Information).

###### 

Likelihood of actinic keratosis (AK) diagnosis in routine care among participants with AK detected by skin screening in a population‐based cohort study (Rotterdam Study, RS)

                                                                               Number of AK diagnosed during RS FBSE   Total                 
  ---------------------------------------------------------------------------- --------------------------------------- ---------- ---------- ----------
  AK detection in skin screening, *n*                                          724                                     328        270        1322
  No routine care based prior AK diagnosis, *n* (%)                            556 (77)                                226 (69)   136 (50)   918 (69)
  Previous routine care based AK diagnosis, *n* (%)                            168 (23)                                102 (31)   134 (50)   404 (31)
  Diagnosis by GP, *n* (%)                                                     68 (40)                                 45 (44)    40 (30)    153 (38)
  Diagnosis by dermatologist,[a](#bjd17632-note-0004){ref-type="fn"} *n* (%)   60 (36)                                 30 (29)    48 (36)    138 (34)
  Diagnosis by both GP and dermatologist, *n* (%)                              40 (24)                                 27 (26)    46 (34)    113 (28)

FBSE, full‐body skin examination; GP, general practitioner. ^a^As derived from GP records. If dermatologist correspondence does not state AK, diagnosis is classified as AK according to the differential diagnosis of the GP.
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### Treatment {#bjd17632-sec-0017}

Of the 1322 participants, 266 (20%) had a previous AK‐related GP consultation, with 455 visits. No active AK‐focused treatment was described in the GP record in 19% of AK‐related visits (85 of 455), and in 16% (*n* = 74) of all first and subsequent visits the patients were referred to secondary care (Table [3](#bjd17632-tbl-0003){ref-type="table"}). Among those with ≥ 10 AKs, the odds of being referred to a specialist during the first AK‐related GP visit were not significantly different from those with one to three AKs (19 of 86 vs. 20 of 108; odds ratio 1·2, 95% CI 0·62--2·52, *P* = 0·54).

###### 

Distribution of treatment modalities for actinic keratosis (AK) by general practitioners (GPs) and dermatologists using three different datasets

                                                                         Treatment by GP                              Treatment by dermatologist                                                                          
  ---------------------------------------------------------------------- -------------------------------------------- ------------------------------------------------- ------------------------------------------------- -----------------------------------------------------
  Patients, *n*                                                          554[a](#bjd17632-note-0006){ref-type="fn"}   266[b](#bjd17632-note-0006){ref-type="fn"}        251[b](#bjd17632-note-0006){ref-type="fn"}        200 056
  Visits, *n*                                                            554                                          455                                               422                                               200 056
  No treatment (incl. no referral), *n* (%)                              42 (8)                                       85 (19)                                           52 (12)                                           44 262 (22)
  Referral, *n* (%)                                                      171 (31)                                     67 (15)                                           N/A                                               N/A
  Treatment by GP, *n* (%)                                               341 (62)                                     297 (65)                                          N/A                                               N/A
  Treatment and subsequent referral                                      41 (7)                                       7 (2)                                             --                                                --
  Treatment by GP only                                                   300 (54)                                     290 (64)                                          --                                                --
  Missing, *n* (%)                                                       0 (0)                                        6 (1)                                             6 (1)                                             0 (0)
  Type of treatment, *n* (%)                                             341 (62)                                     297 (65)[c](#bjd17632-note-0006){ref-type="fn"}   364 (86)[c](#bjd17632-note-0006){ref-type="fn"}   155 794 (78)[d](#bjd17632-note-0006){ref-type="fn"}
  Cryotherapy                                                            251 (74)                                     239 (78)                                          203 (56)                                          64 047 (41)
  Topical treatment of AK[e](#bjd17632-note-0006){ref-type="fn"}         23 (7)                                       7 (2)                                             76 (21)                                           20 908 (13)
  Photodynamic therapy                                                   --                                           --                                                19 (5)                                            3150 (2)
  Surgical                                                               28 (8)                                       12 (4)                                            43 (12)                                           26 324 (17)
  Other medical treatment of AK[f](#bjd17632-note-0006){ref-type="fn"}   38 (11)                                      42 (14)                                           22 (6)                                            981 (1)
  Other[g](#bjd17632-note-0006){ref-type="fn"}                           1 (0·3)                                      5 (2)                                             1 (0·3)                                           40 384 (26)

Different datasets are not comparable. When methyl aminolaevulinate cream is mentioned, this is not scored since the only indication for this treatment is as a primer for photodynamic therapy. DIS, DRG Information System; IPCI, Integrated Primary Care Information; N/A, not applicable; RS, Rotterdam Study.

^a^In 554 of the 1000 patients included from the IPCI GP database, AK was in the differential diagnosis of the GP. ^b^Of the 1322 participants screened in the RS, 266 had an AK‐related visit at the GP and 251 at the dermatologist. ^c^Total numbers add up to \> 100% as patients may have received multiple treatments for their AK(s). ^d^For each AK‐related visit only the most invasive treatment was scored. ^e^Relevant treatment of AK: 5‐fluorouracil, imiquimod and ingenol mebutate gel. For the hospital claims data this was only registered if patient picked up their prescribed treatment within 7 days after the outpatient clinic visit. ^f^Included in other medical treatment of AK: nontopical treatment, tretinoin, salicylic acid, ureum, lanette, fucidine, cetomacrogol, diclofenac, antimycotic, antibacterial. ^g^Other treatments are: laser, coagulation, unknown.

John Wiley & Sons, Ltd

Patients were treated by a GP in 297 of the 455 AK‐related visits (65%), at which cryotherapy was mostly applied (78%, 239 of 297). Among patients only seen by the GP, the proportion of visits during which cryotherapy was applied increased significantly with the number of AKs (52% in one to three AKs to 68% in ≥ 10 AKs, *P* = 0·04; Data [S1](#bjd17632-sup-0001){ref-type="supplementary-material"} tables; see Supporting Information). In 2% of the 297 AK visits during which a treatment was given by the GP, a topical AK therapy was prescribed, while other treatments unrelated to AK (e.g. antibacterial ointments) were prescribed in 14% of visits.

Of the 1322 patients with AK, 251 had at least one previous dermatology visit with 422 visits (Table [3](#bjd17632-tbl-0003){ref-type="table"}). No treatment was given during 52 (12%) visits and in 364 of 422 (86%) of all visits the patient was treated by the dermatologist; in the remaining six visits information was missing. Cryotherapy was the most used treatment (56%, 203 of 364), followed by field treatment (26%), of which photodynamic therapy was used during 19 visits. For patients treated by the dermatologist the proportion of visits during which the field treatment was selected increased significantly with the number of AKs (20% in one to three AKs to 32% in ≥ 10 AKs, *P* = 0·02; Data [S1](#bjd17632-sup-0001){ref-type="supplementary-material"} tables; see Supporting Information).

### Follow‐up {#bjd17632-sec-0018}

Of the 266 individuals with AK seen by the GP, 166 patients (62%) had no second visit for AK recorded over a median follow‐up time of 2·8 years (Table [4](#bjd17632-tbl-0004){ref-type="table"}); although this group also contains patients referred to the dermatologist. The remaining 100 patients had 189 subsequent visits for AK, 24% of follow‐up visits were within 3 months after the initial treatment and 22% in the year following the first GP visit. Among 1322 RS cohort participants with AK, a BCC was recorded in PALGA among 7% (*n* = 88) and an SCC in 4% (*n* = 50) of participants during a median follow‐up period of 2·8 years (interquartile range 1·3--4·4). The risk of any KC (i.e. not AK‐lesion specific) increased from 9% (65 of 724) for individuals with one to three AKs to 16% (43 of 270) for those with ≥ 10 AKs. The relative risk of developing a histologically confirmed KC was 3·0 (95% CI 2·4--3·9) for the group with AK compared with those without AK in the RS (111 of 1322 vs. 116 of 4193).

###### 

Actinic keratosis (AK)‐related healthcare visits and subsequent (pre)malignancies among patients with AK

  Database                                   GP records                                        Dermatologist records                                     
  ------------------------------------------ ------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------
  Patients, *n*                              486[d](#bjd17632-note-0007){ref-type="fn"}        266                                                       200 056
  Follow‐up time (years)                     Median 5·6, IQR 5·1--6·2                          Median 2·8, IQR 1·3--4·4                                  Up to 5 years[e](#bjd17632-note-0007){ref-type="fn"}
  Follow‐up                                                                                                                                              
  Number of AK‐related follow‐up visits                                                                                                                   
  0                                          149 (31)                                          166 (62)                                                  87 302 (44)
  ≥ 1                                        337 (69)[a](#bjd17632-note-0007){ref-type="fn"}   100 (38)                                                  112 754 (56)
  Visits per period, *n* (%)                 N/A                                               189 visits in 100 patients                                317 642 visits in 112 754 patients
  \<3 months                                 --                                                46 (24)                                                   101 382 (32)
  3--12 months                               --                                                42 (22)                                                   86 766 (27)
  \> 12 months                               **--**                                            94 (50)                                                   129 494 (41)
  Unknown                                    --                                                7 (4)                                                     0 (0)
  Cutaneous lesions                                                                                                                                      
  Subsequent cutaneous malignancy, *n* (%)                                                     138 (10) of 1322[b](#bjd17632-note-0007){ref-type="fn"}   19 178 (11)[c](#bjd17632-note-0007){ref-type="fn"}
  Basal cell carcinoma                       72 (15)                                           88 (7)                                                    N/A
  Squamous cell carcinoma                    36 (7)                                            50 (4)                                                    N/A

DIS, DRG Information System; GP, general practitioner; IPCI, Integrated Primary Care Information; IQR, interquartile range; N/A, not applicable. ^a^486 patients with confirmed AK in the cohort 2009/2010. ^b^All patients were followed up to mid‐2016, independent of the year of initial treatment. ^c^Total of patients with one or more skin cancer related GP visits (not AK specific). ^d^Cases were identified using linkage with the Dutch Pathology Registry (PALGA) in the period from the date of skin screening based AK diagnosis until the end of 2015. Median follow‐up period for this group is 3·7 (IQR 1·3--4·6). ^e^Includes patients with a subsequent claim for diagnostic code 0017 for cutaneous malignancy, including basal cell carcinoma, squamous cell carcinoma, (lentigo maligna) melanoma, lymphoma, cutaneous metastatic disease and other cutaneous malignancies; no further differentiation available. Only the first claim for cutaneous malignancy could be extracted.
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Routine general practitioner records: Integrated Primary Care Information database {#bjd17632-sec-0019}
----------------------------------------------------------------------------------

### Diagnosis {#bjd17632-sec-0020}

Among the 1000 randomly selected eligible patients who mentioned AK for the first time in the patient record, 47% (*n* = 471) were men and the mean ± SD age was 69 ± 12 years (Table [1](#bjd17632-tbl-0001){ref-type="table"}). Among these 1000 patients, 400 were included based on correspondence from dermatologists in the GP record and were not seen by the GP for AK during the preceding year. The remaining 600 patients had a GP visit including an AK diagnosis, of which AK Was in the differential diagnosis by GPs in 554 cases. In 97%, AKs were clinically diagnosed and 3% were confirmed by histology.

### Treatment {#bjd17632-sec-0021}

Over 60% (*n* = 341) of the 554 patients with AK in the differential diagnosis were treated by their GP, predominantly with cryotherapy (251 of 341, 74%; Table [3](#bjd17632-tbl-0003){ref-type="table"}), followed by surgery (8%) and topical treatment (7%). Other medical treatments (e.g. antibacterial ointments) were prescribed by GPs in 11% (*n* = 38) of patients with the first mention of AK in their record. In 8% (42 of 554) the GP recorded an AK and did not describe any further treatment or referral suggesting a wait‐and‐see policy. One‐third (171 of 554) of patients with AK were referred to the dermatologist at the time of the first clinical diagnosis.

### Follow‐up {#bjd17632-sec-0022}

During a median follow‐up of 5·6 years of 486 patients with a confirmed AK in the 2009/2010 cohort, 69% had a second GP visit related to cutaneous (pre)malignancies (not AK specific; Table [4](#bjd17632-tbl-0004){ref-type="table"}). Subsequent BCCs were recorded among 72 patients (15%) and SCCs among 36 of the 486 patients (7%).

Among the 38 patients who initially received treatments not indicated for AK, four subsequently received cryotherapy, four again received treatments not indicated for AK and 30 received no further treatment during follow‐up.

Nationwide hospital claims: DRG Information System {#bjd17632-sec-0023}
--------------------------------------------------

Using open source data, 98 435 (13%) of the 768 770 dermatology‐related claims in 2015 were due to cutaneous premalignancies, including AK. Between 2011 and 2015, 200 056 claims of incidental patients with AK without a previous cutaneous malignancy were identified (Data [S1](#bjd17632-sup-0001){ref-type="supplementary-material"}; see Supporting Information).

### Treatment {#bjd17632-sec-0024}

In 22% (44 262 of 200 056) of the first AK‐related visits, no treatment was registered. Of the 155 794 claims that included a treatment, 41% involved cryotherapy, 13% topical AK treatment, 2% photodynamic therapy, 17% a surgical procedure (i.e. biopsy or excision) and 26% coagulation or laser therapy (Table [3](#bjd17632-tbl-0003){ref-type="table"}).

### Follow‐up {#bjd17632-sec-0025}

All 200 056 patients with AK were followed until 31 December 2015, with 517 698 dermatology outpatient clinic visits. Fifty‐six per cent of the 200 056 patients had at least one dermatology follow‐up visit, with a total of 317 642 visits (Table [4](#bjd17632-tbl-0004){ref-type="table"}). Almost two‐thirds of the follow‐up visits were in the first year after initial treatment, with an average of 1·8 visits per patient. Thirteen per cent of the 317 642 follow‐up visits included a surgical procedure and 17% cryotherapy.

In the cohort with an initial claim for AK in 2011 (*n* = 46 415), and thus with the most extended follow‐up time of 5 years, 18% (*n* = 8390) of the patients had a subsequent claim for a cutaneous malignancy.

Discussion {#bjd17632-sec-0026}
==========

Although AK is a common skin condition that accounts for at least 10% of all dermatological visits, a substantial proportion of the general population seems unaware of having AK. In both primary and secondary care, cryotherapy was most commonly used. Field therapy was the second option for dermatologists, while GPs only rarely applied these topical therapies. The number of AKs only modestly increased the likelihood of having an AK‐related GP consultation, while it did not affect the risk of being referred to secondary care. Follow‐up schedules seem to be extensive in secondary care.

This study shows that half of the people with ≥ 10 AKs in the population‐based cohort had no previous consultation. As GP consultations are mostly patient driven, it is most likely the result of patients being unaware of having AKs and the potential increased risk to develop KC. Limited awareness in the general population implies the potential of underdiagnosis and undertreatment of AK. Although not all AKs warrant treatment, this does raise concerns with extensive AK (i.e. multiple AKs or field change).[2](#bjd17632-bib-0002){ref-type="ref"} As a clinical biomarker of extensive ultraviolet exposure, we have demonstrated that the number of AKs correlates with an increased risk of KC, which may contribute to the growing burden of KC.[2](#bjd17632-bib-0002){ref-type="ref"}, [3](#bjd17632-bib-0003){ref-type="ref"}, [17](#bjd17632-bib-0017){ref-type="ref"}, [18](#bjd17632-bib-0018){ref-type="ref"} Therefore, appropriate awareness about AK and its treatment, particularly for patients with ≥ 10 AKs, is important for both the general population and GPs, which is also advocated by the US Preventative Services Task Force.[5](#bjd17632-bib-0005){ref-type="ref"}, [19](#bjd17632-bib-0019){ref-type="ref"}, [20](#bjd17632-bib-0020){ref-type="ref"}, [21](#bjd17632-bib-0021){ref-type="ref"} As AKs are often located on visible skin sites such as the face and scalp, GPs may have an important role in increasing the awareness of AKs.[3](#bjd17632-bib-0003){ref-type="ref"}, [19](#bjd17632-bib-0019){ref-type="ref"}, [22](#bjd17632-bib-0022){ref-type="ref"} Unfortunately, from our data we were unable to estimate the extent to which the AKs have been noted by GPs. However, it may be questioned if GPs being proactive about AKs is feasible, as patients are already bringing multiple problems to the brief consultations with the GP; therefore, a low‐risk condition such as AK may not be of the highest priority for either the patient or the GP.[23](#bjd17632-bib-0023){ref-type="ref"}, [24](#bjd17632-bib-0024){ref-type="ref"}, [25](#bjd17632-bib-0025){ref-type="ref"}

Relatively recently (June 2017) the first Dutch GP guidelines for 'suspicious skin lesions' were published, while secondary care AK‐specific guidelines have been available since 2010.[19](#bjd17632-bib-0019){ref-type="ref"}, [26](#bjd17632-bib-0026){ref-type="ref"}, [27](#bjd17632-bib-0027){ref-type="ref"} This might have affected different (awareness and) management of AK between primary and secondary care. Cryotherapy was the main treatment modality used by GPs, and interestingly the number of cryotherapy treatments significantly increased with more extensive AK. The recently introduced GP guidelines recommend cryotherapy for five or fewer AKs, which is comparable with international guidelines.[2](#bjd17632-bib-0002){ref-type="ref"}, [19](#bjd17632-bib-0019){ref-type="ref"}, [28](#bjd17632-bib-0028){ref-type="ref"}, [29](#bjd17632-bib-0029){ref-type="ref"}, [30](#bjd17632-bib-0030){ref-type="ref"} The limited treatment modalities used by GPs may be a reflection of limited familiarity of GPs with different treatment modalities for AK, possibly because of the undersupply of dermatology training in both GP specialist training and continuing medical education programmes in many countries.[31](#bjd17632-bib-0031){ref-type="ref"}, [32](#bjd17632-bib-0032){ref-type="ref"}, [33](#bjd17632-bib-0033){ref-type="ref"}, [34](#bjd17632-bib-0034){ref-type="ref"}, [35](#bjd17632-bib-0035){ref-type="ref"}, [36](#bjd17632-bib-0036){ref-type="ref"}, [37](#bjd17632-bib-0037){ref-type="ref"}, [38](#bjd17632-bib-0038){ref-type="ref"}, [39](#bjd17632-bib-0039){ref-type="ref"}, [40](#bjd17632-bib-0040){ref-type="ref"} Effective and successful implementation of the primary care guidelines has the potential to fill this educational gap in the short term, and may result in the decreased use of nonindicated treatments (such as antibiotics) and structuring the use of suitable treatments by GPs. However, without proper dermatology training for GPs, clinical guidelines are not sufficient to improve patient care.[41](#bjd17632-bib-0041){ref-type="ref"} Sufficient education, time and resources are pivotal for the successful management of AK in primary care.

A substantial proportion of patients with AK were referred to the dermatologists (38% at the first encounter in primary care), which was unrelated to the extent of AK. The group of patients solely referred for AK is already significant with 40 000 new patients being referred to the dermatologists per year within a population of 17 million inhabitants. However, this is still a substantial underestimation of the total AK load in secondary care as this excludes patients who also have cutaneous malignancies. Given these large numbers of patients with AK, AK being managed rather than cured, and overburdening in secondary care, both national and international guidelines support the concept that the majority of patients with AK could and should be managed in primary care.[2](#bjd17632-bib-0002){ref-type="ref"}, [19](#bjd17632-bib-0019){ref-type="ref"}, [28](#bjd17632-bib-0028){ref-type="ref"}, [29](#bjd17632-bib-0029){ref-type="ref"} Many countries including the Netherlands, have some level of gatekeeping in access to specialists, although the extent varies widely between countries.[42](#bjd17632-bib-0042){ref-type="ref"}, [43](#bjd17632-bib-0043){ref-type="ref"}, [44](#bjd17632-bib-0044){ref-type="ref"}, [45](#bjd17632-bib-0045){ref-type="ref"} However, with skin cancer GP education being side‐lined in both a national and an international perspective, successful AK management (and thus efficient gatekeeping) is compromised.[32](#bjd17632-bib-0032){ref-type="ref"}, [33](#bjd17632-bib-0033){ref-type="ref"}, [34](#bjd17632-bib-0034){ref-type="ref"}, [37](#bjd17632-bib-0037){ref-type="ref"}, [38](#bjd17632-bib-0038){ref-type="ref"}, [39](#bjd17632-bib-0039){ref-type="ref"}, [46](#bjd17632-bib-0046){ref-type="ref"}, [47](#bjd17632-bib-0047){ref-type="ref"} Increasing the familiarity of GPs with AK management by extending dermatology training for GPs may increase the likelihood of treating the condition themselves, reducing the use of nonindicated treatments (e.g. antibiotics) and limiting patients entering secondary care.[19](#bjd17632-bib-0019){ref-type="ref"}, [37](#bjd17632-bib-0037){ref-type="ref"}, [40](#bjd17632-bib-0040){ref-type="ref"}, [48](#bjd17632-bib-0048){ref-type="ref"}, [49](#bjd17632-bib-0049){ref-type="ref"} Examples of the effect of additional training can be seen with dedicated and specialized GPs in Australia and the U.K., where they have a greater role in skin cancer management.[50](#bjd17632-bib-0050){ref-type="ref"}, [51](#bjd17632-bib-0051){ref-type="ref"}, [52](#bjd17632-bib-0052){ref-type="ref"} In addition, further structuring of AK management, including explicit criteria for referral (e.g. AK not responding to treatment, AK in immunosuppressed patients, AK with the potential of SCC), may provide a substantive potential to lower the burden in secondary care.[19](#bjd17632-bib-0019){ref-type="ref"}, [53](#bjd17632-bib-0053){ref-type="ref"}

In addition to efforts directed towards the general population and primary care, this study also identified potential areas for improvement in secondary care. Firstly, in the case of extensive AKs (i.e. *n* ≥ 10), field treatment is recommended in national and international guidelines.[2](#bjd17632-bib-0002){ref-type="ref"}, [27](#bjd17632-bib-0027){ref-type="ref"} However, these guidelines seem to be followed inconsistently, with only 32% of patients with extensive AK receiving field treatment (although significantly higher than in the group with mild AK). Secondly, the majority of patients with AK seen by the dermatologists had at least one follow‐up visit, whereas the guidelines recommend follow‐up in secondary care only for high‐risk patients (e.g. those with immunosuppression).[2](#bjd17632-bib-0002){ref-type="ref"}, [27](#bjd17632-bib-0027){ref-type="ref"} Comparable high follow‐up rates among patients with AK were observed in the U.K.[52](#bjd17632-bib-0052){ref-type="ref"} These extensive follow‐up rates by dermatologists for what may be considered low‐risk care have the potential for overtreatment, and motives for this need to be explored.

A strength of this study is that multiple databases were analysed to obtain a comprehensive overview of AK‐related care, which has not been described before. The combination of a population‐based cohort and routine GP records is a unique way to identify patients with AK who never visited a GP or were not previously diagnosed in routine care, and to study the occurrence of KCs related to AK extensiveness. Furthermore, by combining primary care and secondary care databases, it provides a more comprehensive overview of the management of patients with AK throughout the care process.

A limitation of routinely collected healthcare data is related to what and how clinical data are recorded. An issue in GP databases was, for example, that clinical AK severity or explicit follow‐up recommendations are usually not recorded. Furthermore, it is possible that a patient visits the GP for a different (main) reason besides AK, which may result in lack of AK registration in the GP record. However, by using these different databases, the findings become more detailed and complementary. In healthcare claims data, it remains uncertain that the claimed care was actually administered. Diagnoses in claims data are less specific. Therefore, we may have included patients with other more rare cutaneous premalignancies (e.g. Bowen disease). This could have resulted in a greater amount of treatments less specific to AK, or higher follow‐up visit rates. However, an algorithm to identify these patients with AK showed a positive predictive value of up to 93%. Finally, some aspects may be specific to the Dutch healthcare system, and this may raise some concerns about the generalizability of our results. However, in many Western countries, primary care is the point of entry in the healthcare system for patients, and in many countries, some level of a gatekeeping system is applied.[45](#bjd17632-bib-0045){ref-type="ref"}, [52](#bjd17632-bib-0052){ref-type="ref"} Therefore, we believe that our observations could be applied to other countries as well. Regardless of the type of healthcare system, AK is a high‐volume condition and therefore comparable issues should be evaluated in other countries to improve the efficiency of care.

In conclusion, AKs are a high‐volume condition, with a significant healthcare impact, but with a seemingly limited familiarity with AK in the general population and possibly among GPs this may lead to the suboptimal use of healthcare resources. We identified areas in AK management that deviate from (both national and international) primary care and secondary care guideline recommendations. Adequate risk differentiation and improved guideline adherence in both primary and secondary care seem warranted to strengthen the vital role of GPs in AK management and to optimize the utilization of healthcare resources. To tailor the efforts needed, motives for AK management diverging from current guidelines among GPs and dermatologists need to be explored.
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